Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Paliperidone ER is a new psychotropic medication for schizophrenia treatment. The studies of
6-week acute treatment and 52-week maintenance treatment showed positive results in patients
with schizophrenia and its clinical improvement may start at Day 4. Some second-generation
antipsychotics have been found that using the first 2 weeks' treatment results to predict the
fourth or sixth week's treatment response is acceptable.
The primary aim of this study is to investigate:
1. . whether the early prediction model used in other atypicals could also be applied in
paliperidone ER.
2. . The changes of metabolic parameters and pharmacokinetics after paliperidone ER
treatment in this study
Phase:
Phase 4
Details
Lead Sponsor:
Taipei City Hospital
Collaborators:
Johnson & Johnson Taiwan Ltd Taipei Institute of Pathology